Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.
Tobacco use, particularly cigarette smoking, is now a global pandemic. The expected morbidity and mortality from smoking-attributable diseases will continue to rise for the next 30 years. In order to reduce this negative impact on worldwide health, effective therapy to aid smoking cessation must be provided to current smokers. Treatment for tobacco dependence involves the combination of behavioural therapies and pharmacological treatment. The most common pharmacological treatments include nicotine replacement therapy and non-nicotine medications, including antidepressants. The antidepressant with the greatest weight of evidence for efficacy in the treatment of tobacco dependence is bupropion. Sustained-release bupropion is approved for the treatment of tobacco dependence in over 50 countries worldwide. The efficacy of bupropion for the treatment of tobacco dependence is attributed to the blockage of dopamine reuptake in the mesolimbic dopaminergic system. This area of the brain is believed to mediate reward for nicotine use and for other drugs of dependence. Randomised, controlled clinical trials have shown that bupropion approximately doubles abstinence rates compared with placebo. In addition, long-term treatment with bupropion may reduce or delay smoking relapse. Bupropion also appears to be effective in the treatment of smokers who have recently relapsed and smokers with other comorbid psychiatric conditions. Bupropion has a good adverse events profile, but the risk exists for serious adverse effects such as seizures. Recent postmarketing surveillance reports have raised safety concerns about bupropion, although no causal relationship between bupropion and the reported serious adverse events or death has been established.
Hays
J Taylor
JT
Mayo Nicotine Dependence Center, Rochester, Minnesota 55905, USA. hays.taylor@mayo.edu
Ebbert
Jon O
JO
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D006801:Humans; D018570:Risk Assessment; D016540:Smoking Cessation; D014029:Tobacco Use Disorder / Q000188:drug therapy*
D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion